webinar register page

The Impact of a Genomic Assay on Urologist Treatment Preference in Active Surveillance-Eligible Men

**This seminar is offered as a HYBRID event: join us IN-PERSON or ONLINE. Please RSVP regardless and indicate your intended mode. The in-person event will be held in Hughes Auditorium of the Lurie Medical Research Building at 303 E. Superior; Chicago. Lunch will be provided for in person attendees and will be available on a first-come, first-served basis.**

Dr. Adam Murphy will summarize the results of a randomized controlled trial assessing the impact of a Genomic Assay on urologists and patients treatment preferences for favorable risk prostate cancer.

Guest:
Adam B. Murphy MD, MBA, MSCI
Assistant Professor of Urology & Preventive Medicine
Northwestern University Feinberg School of Medicine

Dr. Murphy is a native Chicagoan who has been studying the health disparities faced by minorities in prostate cancer, including Black and Hispanic men. We have been looking at the role of vitamin D deficiency, genetics, and biomarkers in men at risk of prostate cancer or diagnosed with prostate cancer. I am also interested in active surveillance for prostate cancer in underserved populations. Clinically, I am interested in general urology and men's health.

This webinar is part of the Translational Applications in Public Health mini-series, which is a collaboration between the Institute for Public Health and Medicine (IPHAM) and the Northwestern University Clinical and Translational Sciences (NUCATS) Institute.

For more public health news, events, and announcements, visit the IPHAM website: https://feinberg.northwestern.edu/ipham

Mar 9, 2023 12:00 PM in Central Time (US and Canada)